Abstract 784P
Background
The incidence of HPV integration is increased during the disease progression from precancerous lesions to carcinoma, and HPV integration is reputed as a key effect to escape eliminations from the host cells. Although HPV integration is identified in HPV-related carcinoma, the mechanisms underlying HPV carcinogenesis remain unclear.
Methods
Here, 6768 HPV integration sites from cervical carcinoma (CESC) and 470 from head & neck carcinoma (HNSC), high-through chromosome conformation capture (Hi-C), ChIP-seq, ChIP-PCR and RNA-seq were analyzed to identify the HPV integration characteristics in HPV-host interactions. Manual HPV-integration cells, an HPV integration mouse model (K14-HPV, FVB/N), and CRISPR-Cas9 knock-out cells were performed to demonstrate the chromatin remolding between universal stripe factors (USFs) and super-enhancers.
Results
In CESC and HNSC, USF motifs were enriched in HPV integration sites and integrated HPV-host interaction regions. In addition, HPV integration sites and integrated HPV-host interaction regions marked increased chromatin accessibility (ATAC-seq) and super-enhancer elements (H3K27ac, H3K4me1, and H3K4me3), with USF motifs enrichment in these regions. By dividing the tumor samples according to HPV status, USF genes were found to be upregulated in CESC and HNSC, which could be validated by tumor samples, manual HPV-integration cells, and the K14-HPV integration mouse model. Furthermore, three-dimensional chromatin analyses reveal the chromatin interactions between USF genes and super enhancers in tumor cells. The expression patterns of USF genes and chromatin interactions between USF genes and the super-enhancer were reversed via super-enhancer CRISPR-Cas9 knock-out, thus reversing malignant phenotypes of tumor cells in vitro and in vivo.
Conclusions
Overall, we identify that HPV integration remodels chromatin interactions between USFs and super enhancers to promote malignant phenotypes in HPV-related carcinoma, which provides insight into the three-dimensional mechanism in HPV-related carcinogenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. CAO.
Funding
National Key R&D Program of China (21YFC2701201) and the National Natural Science Foundation of China (82072895, 82141106, and 82203453).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11